Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

PD-1–refractory advanced melanoma: how do we get to the finish line?

Highlights in melanoma from ASCO 2024

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

ASCO 2024: Lung cancer roundup

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM